2型糖尿病患者中磺脲类药物所致低血糖的药物遗传学：SUCLINGEN研究
Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study.
作者信息
Loganadan Navin Kumar, Huri Hasniza Zaman, Vethakkan Shireene Ratna, Hussein Zanariah
机构信息
Department of Pharmacy, Putrajaya Hospital, Precinct 7, Putrajaya, 62250, Malaysia.
Faculty of Pharmacy, University of Malaya, Kuala Lumpur, 50603, Malaysia.
出版信息
Pharmacogenomics. 2021 Nov;22(16):1057-1068. doi: 10.2217/pgs-2021-0059. Epub 2021 Oct 19.
This study investigated the incidence of sulfonylurea-induced hypoglycemia and its predictors in Type 2 diabetes (T2D) patients. In this prospective, observational study, T2D patients on maximal sulfonylurea-metformin therapy >1 year were enrolled. Hypoglycemia was defined as having symptoms or a blood glucose level <3.9 mmol/l. Of the 401 patients, 120 (29.9%) developed sulfonylurea-induced hypoglycemia during the 12-month follow-up. The rs757110, rs5219, rs7756992 and rs2237892 gene polymorphisms were not associated with sulfonylurea-induced hypoglycemia (p > 0.05). Prior history of hypoglycemia admission (odds ratio = 16.44; 95% CI: 1.74-154.33, p = 0.014) independently predicted its risk. Sulfonylurea-treated T2D patients who experienced severe hypoglycemia are at increased risk of future hypoglycemia episodes.
本研究调查了2型糖尿病（T2D）患者中磺脲类药物诱发低血糖的发生率及其预测因素。在这项前瞻性观察研究中，纳入了接受最大剂量磺脲类-二甲双胍治疗超过1年的T2D患者。低血糖定义为出现症状或血糖水平<3.9 mmol/l。在401例患者中，120例（29.9%）在12个月的随访期间发生了磺脲类药物诱发的低血糖。rs757110、rs5219、rs7756992和rs2237892基因多态性与磺脲类药物诱发的低血糖无关（p>0.05）。既往低血糖住院史（比值比=16.44；95%可信区间：1.74-154.33，p=0.014）可独立预测其风险。经历过严重低血糖的磺脲类药物治疗的T2D患者未来发生低血糖事件的风险增加。
Zotero 插件